Swiss biotech company Memo Therapeutics raises $15.5m in Series B round
Memo Therapeutics has raised CHF14 million ($15.56 million) in a Series B financing round towards the clinical development of potent antibodies for the immunotherapy of Covid-19. The proceeds from the funding round will also help the Swiss biotech company in developing antibodies for BK virus infection in kidney transplant patients. The funding round was led […]